These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 9252661

  • 1. A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer.
    Kawano Y, Watanabe M, Kubota T, Nishibori H, Kurihara N, Teramoto T, Kitajima M.
    Anticancer Res; 1997; 17(4A):2449-53. PubMed ID: 9252661
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
    Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y.
    Cancer Res; 1991 Apr 15; 51(8):2199-204. PubMed ID: 1706961
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R, Yoshida H, Yanagawa T, Sato M.
    J Biol Response Mod; 1989 Oct 15; 8(5):488-500. PubMed ID: 2552025
    [Abstract] [Full Text] [Related]

  • 4. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y.
    Anticancer Res; 1998 Oct 15; 18(1A):17-24. PubMed ID: 9568050
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y, Sawada T, Nishihara T, Yamashita Y, Ohira M, Ho JJ, Kim YS, Hirakawa-Y S Chung K.
    Int J Oncol; 2002 Sep 15; 21(3):649-54. PubMed ID: 12168113
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
    Watanabe M, Kubota T, Kitajima M, Hakomori S.
    Cancer Immunol Immunother; 1993 Sep 15; 37(4):245-50. PubMed ID: 8348564
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M, Ohta R, Varela JC, Song H, Tomlinson S.
    Cancer Res; 2007 Oct 01; 67(19):9535-41. PubMed ID: 17909064
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
    Hihara J, Yamaguchi Y, Minami K, Noma K, Toge T.
    Anticancer Res; 1999 Oct 01; 19(2A):1077-84. PubMed ID: 10368657
    [Abstract] [Full Text] [Related]

  • 13. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N, Hori T, Ohgaki K, Inamoto T, Kodama H, Tobe T.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
    Mizukami M, Hanagiri T, Yasuda M, Kuroda K, Shigematsu Y, Baba T, Fukuyama T, Nagata Y, So T, Ichiki Y, Sugaya M, So T, Takenoyama M, Sugio K, Yasumoto K.
    Cancer Res; 2007 Sep 01; 67(17):8351-7. PubMed ID: 17804751
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
    Oshikawa T, Okamoto M, Ohe G, Furuichi S, Nishikawa H, Uddin Ahmed S, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2003 May 01; 3(5):643-55. PubMed ID: 12757734
    [Abstract] [Full Text] [Related]

  • 16. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.
    Lung Cancer; 2009 Jan 01; 63(1):23-31. PubMed ID: 18524412
    [Abstract] [Full Text] [Related]

  • 17. [Local immunotherapy for cancer].
    Hattori T, Niimoto M, Toge T, Hamamoto S, Seto Y, Kameda A, Tomoda S.
    Nihon Geka Gakkai Zasshi; 1984 Sep 01; 85(9):1157-61. PubMed ID: 6503978
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1325-32. PubMed ID: 16489090
    [Abstract] [Full Text] [Related]

  • 19. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
    Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H.
    Cancer Res; 2008 Dec 01; 68(23):9832-8. PubMed ID: 19047163
    [Abstract] [Full Text] [Related]

  • 20. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy.
    Kanellos J, Pietersz GA, McKenzie IF.
    J Natl Cancer Inst; 1985 Aug 01; 75(2):319-32. PubMed ID: 2991647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.